drugset
drugset / Trial / NCT03579966

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

NCT03579966 ↗

Phase 3 Terminated 63 enrolled Catalyst Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.

Timeline

Start
2018-06-11
Primary completion
2022-08-05
Completion
2022-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amifampridine Small molecule 10 mg —

Indications

AChR+ myasthenia gravis muscle-specific tyrosine kinase-associated myasthenia gravis